Introduction
============

Minimal change disease (MCD) is a common pathological type of nephrotic syndrome (NS), and its typical characteristic is the diffuse effacement of podocyte foot processes observed by electron microscope ([@ref-13]). The actin of foot process is linked with slit diaphragm, which is important for renal glomerular filtration function. MCD is commonly seen in child patients with NS. According to the reports, about 80% MCD cases are aged less than 10 years old. The incidence of MCD in adults is lower than that in children ([@ref-5]; [@ref-14]; [@ref-18]; [@ref-29]). In our country, the incidence of adult MCD patients in NS patients is less than 25% ([@ref-6]; [@ref-30]). At present, renal biopsy, which is an invasive examination, is required for most glomerulopathy diagnoses. Although it can offer the diagnosis and testing information for the doctors, renal biopsy may cause complications, such as bleeding. Moreover, some patients can not accept the renal biopsy, leading to the absence of timely diagnosis ([@ref-8]; [@ref-22]; [@ref-26]). Therefore, a non-invasive model is urgently needed to discriminate MCD.

It is reported that mathematical model, like classification and regression tree (CART) model can be used as a method to classify different diseases ([@ref-15]; [@ref-28]). At present time, the diagnostic model based on data analysis has become the focus of disease diagnosis, and it also can be used in the noninvasive diagnosis ([@ref-2]). Moreover, some reports have shown that the classification equations have been used in kidney diseases.

In present study, with the purpose of classifying MCD and other kidney diseases, we established a diagnostic model based on the clinical parameter. Additionally, we also conducted common statistical analyses, including Chi-square tests, logistic analysis and receiver operating characteristic (ROC) analysis.

Methods
=======

Study object
------------

This study was approved by the Medical Ethics Committee of the Chinese PLA General Hospital, and written consents were obtained from all patients. The inclusion criteria of the current research were listed as follows: (1) all the participants were the first time to be admitted into the Department of Nephrology of our hospital; (2) adult patients; (3) no one accepted the renal biopsy before entering our hospital; (4) no one accepted any treatments, including hypertension treatment or hyperlipidemia treatment; (5) no one suffered from any tumors, except hypertension, diabetes, hepatitis or lupus erythematosus; (6) all patients accepted renal biopsy during their hospitalization. The following exclusion criteria were applied in our study: (1) the patients could not accept renal biopsy; (2) no complete clinical data were provided. According to the inclusion and exclusion criteria, 798 patients were finally recruited, containing 47 MCD patients and 751 patients with other kidney diseases.

Samples and biological parameters
---------------------------------

For all the 798 patients, their blood samples were collected on the second day after entering hospital. Then, blood coagulation test, blood routine examination and clinical biochemistry testing were performed. The demographic data as well as clinical and laboratory examination of all patients were recorded, including age, gender, presence of other diseases, physical examination, and so on.

Statistical analysis
--------------------

In this study, all statistical analyses were performed using SPSS 19.0 and GraphPad Prism 5. The data were summarized and presented as means ± SD. The biological indicators of the two groups were assessed by using *t*-tests. Logistic regression was employed to establish the diagnostic model. The diagnostic value of the constructed model was examined via performing ROC analysis. *P* values less than 0.05 were considered to be statistically significant in this paper.

Results
=======

The characteristics of patients
-------------------------------

The tested biological parameters were all listed in [Table 1](#table-1){ref-type="table"}, including Anti-phospholipase A2 receptor (anti-PLA2R), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Total protein (TP), Albumin (ALB), Total bilirubin (TB), Direct bilirubin (DB), Alkaline phosphatase (ALP), γ-Glutamyltransferase (GGT), Glucose (GLU), Urea nitrogen (UN), Creatinine (Cr), Uric acid (Ua), Total cholesterol (CH), Triglyceride (TG), Creatine kinase (CK), Lactate dehydrogenase (LDH), High density lipoprotein cholesterol (HDL), Low density lipoprotein cholesterol (LDL), Thrombin time (TT), Prothrombin time (PT), Plasma fibrinogen (FIB), D-dimer (D2), Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM), Immunoglobulin E (IgE), Complement 3 (C3), Complement 4 (C4) and Body mass index (BMI). Moreover, the reference ranges of them were also listed in the table. The demographic data and history of diseases of these two groups were recorded in [Table 2](#table-2){ref-type="table"}. We found that the rates of hypertension and diabetes were declined in MCD patients compared with the patients with other kidney diseases. In MCD group, the numbers of patients less than 40 years old and more than 40 years old were about the same, and the similar result was found in the group of other kidney diseases. We observed more male patients than female patients in both groups. Besides, most patients of the two groups had no hypertension, diabetes or hepatitis. The BMI value was 25.03 ± 4.66 in MCD group, and the data for the group of other kidney disease was 25.45 ± 4.37.
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###### The biological parameters in this study.

The tested biological parameters.

![](peerj-06-4237-g003)

  Index full name                        Abbreviation   Reference range
  -------------------------------------- -------------- ------------------
  Anti-phospholipase A2 receptor         Anti-PLA2R     
  Alanine aminotransferase               ALT            0--40 U/L
  Aspartate aminotransferase             AST            0--40 U/L
  Total protein                          TP             55--80 g/L
  Albumin                                ALB            35--50 g/L
  Total bilirubin                        TB             0--21 µmol/L
  Direct bilirubin                       DB             0--8.6 µmol/L
  Alkaline phosphatase                   ALP            0--130 U/L
  γ-Glutamyltransferase                  GGT            0--50 U/L
  Glucose                                GLU            3.4--6.2 mmol/L
  Urea nitrogen                          UN             1.8--7.5 mmol/L
  Creatinine                             Cr             30--110 µmol/L
  Uric acid                              Ua             104--444 µmol/L
  Total cholesterol                      CH             3.1--5.7 mmol/L
  Triglyceride                           TG             0.4--1.7 mmol/L
  Creatine kinase                        CK             2--200 U/L
  Lactate dehydrogenase                  LDH            40--250 U/L
  High density lipoprotein cholesterol   HDL            1--1.6 mmol/L
  Low density lipoprotein cholesterol    LDL            0--3.4 mmol/L
  Thrombin time                          TT             16.0--18.0 s
  Prothrombin time                       PT             11.0--15.0 s
  Plasma fibrinogen                      FIB            200--400 mg/dL
  D-dimer                                D2             0.0--0.5  µg/L
  Immunoglobulin A                       IgA            70--180 mg/dl
  Immunoglobulin G                       IgG            700--1,600 mg/dl
  Immunoglobulin M                       IgM            40--230 mg/dl
  Immunoglobulin E                       IgE            0--100 IU/ml
  Complement 3                           C3             90--180 mg/dl
  Complement 4                           C4             10--40 mg/dl
  Body mass index                        BMI            18.5--24.99
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###### Basic information of the two groups.

The demographic data and history of diseases of these two groups.
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                 MCD group (*n* = 47)   Group of other kidney diseases (*n* = 751)   *P* value
  -------------- ---------------------- -------------------------------------------- -----------
  Age                                                                                0.452
  \<40           25                     357                                          
  ≥40            22                     394                                          
  Gender                                                                             0.685
  Male           30                     457                                          
  Female         17                     294                                          
  Hypertension                                                                       0.000
  Yes            7                      363                                          
  No             40                     388                                          
  Diabetes                                                                           0.041
  Yes            2                      113                                          
  No             45                     638                                          
  Hepatitis                                                                          0.050
  Yes            0                      57                                           
  No             47                     694                                          
  BMI            25.03 ± 4.66           25.45 ± 4.37                                 0.895

The comparison of biochemical indicators between two groups
-----------------------------------------------------------

In order to explore the association between biochemical indicators and MCD, student's *t*-test was performed. As shown in [Table 3](#table-3){ref-type="table"}, the results showed that among the 28 biochemical indicators, 13 indicators including anti-PLA2R (*P* = 0.000), TP (*P* = 0.000), ALB (*P* = 0.000), DB (*P* = 0.002), Cr (*P* = 0.000), CH (*P* = 0.000), LDH (*P* = 0.007), HDL (*P* = 0.000), LDL (*P* = 0.000), TT (*P* = 0.000), FIB (*P* = 0.000), IgA (*P* = 0.008) and C3 (*P* = 0.019) were significantly different between the two groups.
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###### The comparison of serological parameters in the two groups.
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  Parameter    MCD group (*n* = 47) (mean ± SD)   Group of other kidney diseases (*n* = 751) (mean ± SD)   *P* value
  ------------ ---------------------------------- -------------------------------------------------------- -----------------------------------------
  Anti-PLA2R   2.00 ± 0.02                        34.22 ± 114.96                                           0.000[^\*^](#table-3fn1){ref-type="fn"}
  ALT          27.00 ± 35.12                      22.61 ± 21.99                                            0.201
  AST          20.79 ± 8.80                       18.82 ± 11.39                                            0.240
  TP           43.32 ± 10.01                      58.33 ± 12.02                                            0.000[^\*^](#table-3fn1){ref-type="fn"}
  ALB          22.68 ± 7.87                       33.94 ± 9.04                                             0.000[^\*^](#table-3fn1){ref-type="fn"}
  TB           7.87 ± 3.64                        8.63 ± 4.40                                              0.177
  DB           1.39 ± 0.99                        1.98 ± 1.32                                              0.002[^\*^](#table-3fn1){ref-type="fn"}
  ALP          69.36 ± 34.22                      66.03 ± 31.66                                            0.835
  GGT          41.43 ± 82.16                      34.00 ± 51.21                                            0.398
  GLU          4.62 ± 0.88                        4.98 ± 1.75                                              0.102
  UN           6.78 ± 4.30                        6.30 ± 3.59                                              0.446
  Cr           82.25 ± 23.15                      104.31 ± 68.19                                           0.000[^\*^](#table-3fn1){ref-type="fn"}
  Ua           345.71 ± 104.69                    366.78 ± 102.00                                          0.198
  CH           8.81 ± 3.23                        5.72 ± 2.21                                              0.000[^\*^](#table-3fn1){ref-type="fn"}
  TG           2.35 ± 1.60                        2.22 ± 1.56                                              0.582
  CK           97.12 ± 88.43                      95.70 ± 99.36                                            0.756
  LDH          204.66 ± 58.78                     182.88 ± 59.31                                           0.007[^\*^](#table-3fn1){ref-type="fn"}
  HDL          1.74 ± 0.76                        1.26 ± 0.84                                              0.000[^\*^](#table-3fn1){ref-type="fn"}
  LDL          6.31 ± 2.81                        3.81 ± 1.84                                              0.000[^\*^](#table-3fn1){ref-type="fn"}
  TT           18.65 ± 2.52                       16.56 ± 1.44                                             0.000[^\*^](#table-3fn1){ref-type="fn"}
  PT           12.85 ± 0.83                       13.15 ± 1.55                                             0.243
  FIB          5.46 ± 1.79                        4.22 ± 1.50                                              0.000[^\*^](#table-3fn1){ref-type="fn"}
  D2           1.07 ± 0.79                        0.98 ± 1.84                                              0.721
  IgA          220.47 ± 92.70                     259.46 ± 117.18                                          0.008[^\*^](#table-3fn1){ref-type="fn"}
  IgM          142.22 ± 64.44                     111.43 ± 126.53                                          0.099
  IgE          445.22 ± 927.74                    205.44 ± 894.09                                          0.090
  C3           116.86 ± 27.12                     107.55 ± 26.38                                           0.019[^\*^](#table-3fn1){ref-type="fn"}
  C4           28.15 ± 10.12                      26.46 ± 9.49                                             0.238

**Notes.**

*P* \< 0.05.

ROC analysis of related characteristics
---------------------------------------

The ROC analysis was conducted to detect the diagnostic value of these 13 indicators, and the results were displayed in [Fig. 1](#fig-1){ref-type="fig"}. We found that in [Fig. 1](#fig-1){ref-type="fig"}, the area under the curves (AUCs) of CH, HDL, LDL, TT and FIB were more than 0.70, and the AUCs of them were 0.807, 0.746, 0.776, 0.817 and 0.713, respectively (*P* = 0.032, 0.037, 0.039, 0.032, and 0.046, respectively).

![The ROC curves of anti-PLA2R, TP, ALB, DB, Cr, CH, LDH, HDL, LDL, TT, FIB, IgA and C3, the related indicators of MCD.\
The ROC analysis was conducted to detect the diagnostic value of these 13 indicators.](peerj-06-4237-g001){#fig-1}

Logistic analysis of the pre-selected parameters
------------------------------------------------

In order to establish the classification models of MCD and other kidney diseases, the logistic analysis was carried out. From [Table 4](#table-4){ref-type="table"}, we could see that CH and TT were risk factors for MCD, and the *P* values of them were both 0.000. Furthermore, the classification equation including CH and TT was as follows: $$\documentclass[12pt]{minimal}
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}{}\begin{eqnarray*}\mathrm{PRE}=1/1+{e}^{-(10.617-0.270\times CH-0.325\times TT)}. \end{eqnarray*}\end{document}$$Then, based on logistic regression of the predicted probability (PRE), the ROC curve of "CH+TT" is presented in [Fig. 2](#fig-2){ref-type="fig"}. From [Fig. 2](#fig-2){ref-type="fig"}, we could see that the AUC of "CH+TT" was 0.827, with the sensitivity of 83.0% and the specificity of 69.8% (*P* = 0.000).

![The ROC curve of "CH+TT" combination from logistic regression of the predicted probability for MCD patients.](peerj-06-4237-g002){#fig-2}

Discussion
==========

MCD is a kind of glomerular disease caused by lesions of the podocyte. Most MCDs are idiopathic nephrotic syndromes among children and adults. MCD is characterized by hypoalbuminemia, hyperlipidemia, proteinuria and edema ([@ref-4]; [@ref-23]). It has been reported that the outcome of MCD is correlated with some elements, such as virus infection, drugs, allergy and even tumors ([@ref-19]; [@ref-24]). At present, the pathogenesis of MCD still remains unclear, but many scholars consider that it may be associated with podocyte injury. Now in clinic, renal biopsy centesis is still the golden standard for the diagnosis of nephropathy ([@ref-1]; [@ref-10]). Renal biopsy centesis is safe and easy operation, but it is invasive with risks ([@ref-9]). Because some patients have suffered from absolute and relative contraindications of renal biopsy ([@ref-25]; [@ref-27]), they refuse to undergo renal biopsy. Since the conditions of hospital are not adequate, renal biopsy can not be implemented in every patient who is suspected to have kidney diseases. Moreover, the histopathological diagnosis of renal biopsy is not stable ([@ref-21]). Consequently, the non-invasive methods with high accuracy are urgently needed for MCD diagnosis are needed.

The mathematical model based on the statistical analysis and computer technique has been used in clinic, such as computed tomography (CT) and nuclear magnetic resonance (NMR) ([@ref-3]; [@ref-16]). [@ref-20] established a new equation of estimated glomerular filtration rate (eGFR), named CKD-EPI, which could assess the stages of kidney diseases (CKD stage) ([@ref-20]). [@ref-11] also established a diagnostic model for IgA nephropathy with 6 serum biochemical parameters, including ALB, CK, Cr, HDL, CA125 and TB ([@ref-11]). Additionally, they certified that this model could be used in the auxiliary diagnosis of IgA nephropathy.

In our study, a diagnostic model was established for MCD, and the enrolled patients were divided into two groups, which were MCD group and group of other kidney diseases. The present paper enrolled 47 MCD patients and 751 patients with other kidney diseases. In the two groups, the numbers of patients older than 40 years old and younger than 40 years old were almost equal. The ratio of male patients and female patients was about 2:1 in both groups, and very few patients suffered from hypertension, diabetes or hepatitis. Besides, the BMI of the two groups also had no significant differences. The *t*-test was implemented to analyze the serum biological indicators, and anti-PLA2R, TP, ALB, DB, Cr, CH, LDH, HDL, LDL, TT, FIB, IgA and C3 were significantly different between the two groups. Like the previous study by Gao and his colleagues, which also found 15 significant different serological indicators between IgAN patients and non-IgAN patients, the ROC analysis was performed to further assess the diagnostic value of the collected parameters ([@ref-12]). In our study, ROC analysis for the 13 indicators revealed that the AUCs of five indicators, CH, HDL, LDL, TT and FIB were more than 0.70. Logistic analysis was performed with CH, HDL, LDL, TT and FIB. The results suggested that CH and TT were risk factors for MCD. Based on logistic regression of the predicted probability on the two indicators, the results of ROC curve revealed that "CH +TT" the AUC of "CH +TT" was 0.827, with the sensitivity of 83.0% and the specificity of 69.8%.
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###### The multivariate logistic regression analysis for the model.

![](peerj-06-4237-g006)

             B        S.E.    Wald     *df*   Sig.   Exp (B)      95% CI   
  ---------- -------- ------- -------- ------ ------ ------------ -------- -------
  CH         −.270    .058    21.720   1      .000   .763         .682     .855
  HDL        −.186    .099    3.516    1      .061   .830         .684     1.008
  TT         −.325    .087    14.145   1      .000   .722         .610     .856
  Constant   10.617   1.449   53.669   1      .000   40,819.656            

In this study, we found that the combined diagnostic value of "CH +TT" was significantly higher than either of them alone. The combined diagnostic model might help improve the diagnosis of MCD, especially for those challenging case. However, the present study has some limitations. Firstly, the sample size of MCD group is not large enough. Moreover, all the patients were collected from a single institution and population, which might cause bias to the final results. Secondly, the specificity was not high in our study, leading to high false positive rate. The diagnostic accuracy of the combined model was 70.4%. In order to improve the diagnosis specificity, we could prioritize diagnosis sensitivity based on the trade-off between diagnosis false positive cases versus omitting true positive cases. According to ROC analysis, the diagnostic specificity was adjusted as 70%, and the sensitivity was 80.9%, while the diagnostic accuracy was 70%, which also hold great potential for clinical application. Thirdly, the diagnostic performance of the constructed models was only verified in the populations collected in the original analysis. A cross-validation was not set to investigate the diagnostic performance of the combined model for MCD in clinic. Additionally, all the MCD cases collected in our study were adults. However, MCD is frequently diagnosed among children, and the adult cases only account for about 10%--15%. The main reasons for childhood MCD include congenital anomalies and inherited disorders, but the diagnostic value of the combined model for the childhood MCD cases remained unknown ([@ref-7]; [@ref-17]). The distinct etiologies may lead to various clinical symptoms, biological parameters, and therapeutic responses. Thus, further investigations are needed to determinate whether the selected biological parameters exerted advantages in diagnosing MCD among children. Further related research will be carried out to address the above issues.

Conclusion
==========

This study has established a diagnostic model based on the clinical parameters to classify MCD and other kidney diseases. The combined diagnostic model with CH and TT could effectively distinguish MCD from other nephrotic syndrome.
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###### ROC-1 raw data

The data used in ROC-1 ([Fig. 1](#fig-1){ref-type="fig"}).

###### 

Click here for additional data file.
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###### ROC-2 raw data

Raw data used in ROC-2 ([Fig. 2](#fig-2){ref-type="fig"}).
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Click here for additional data file.
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###### [Table 3](#table-3){ref-type="table"} raw data
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Click here for additional data file.
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###### Logistic raw data

Raw data used in the logistic analysis.

###### 

Click here for additional data file.
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